艾易舒注射液治疗非小细胞肺癌临床疗效的系统评价  

The systematic review of clinical efficacy of Aiyishu injection in treatment of non-small cell lung cancer

作　　者：杨兴华[1] 于飞[2] 何电[1] 胡予涵 

机构地区：[1]首都医科大学公共卫生学院临床流行病学北京市重点实验室,北京100069 [2]首都医科大学中医药学院,北京100069

出　　处：《中华临床医师杂志（电子版）》2015年第12期89-93,共5页Chinese Journal of Clinicians(Electronic Edition)

摘　　要：目的系统评价艾易舒注射液在非小细胞肺癌患者治疗中的作用。方法计算机检索Cochrane图书馆、MEDLINE、CBM、CNKI、万方等数据库,时限从建库至2014年4月,纳入随机对照试验。2名评价者独立评价并交叉核对研究质量后采用Rev Man 5.2软件分析。结果最终纳入19项随机对照试验、1 279例受试者,质量等级多为B。结果表明:艾易舒射液相比对照组可提高化疗有效率(RR=1.42,95%CI:1.25,1.61)、改善患者生活质量(RR=1.63,95%CI:1.26,2.11)、缓解临床症状(RR=1.54,95%CI:1.28,1.86),并减轻骨髓抑制毒性作用(白细胞下降率)(RR=0.47,95%CI:0.35,0.63)和消化道症状发生率(RR=0.73,95%CI:0.61,0.88)。结论艾易舒注射液可提高非小细胞肺癌化疗的治疗有效率,且减轻毒副作用,但目前的研究样本量较小,建议开展多中心的随机对照试验。Objective To evaluate the effectiveness and safety of the Disodium Cantharidinate and Vitamin B6 Injection （Aiyishu） combined chemotherapy for lung carcinoma. Methods Searched MEDLINE, CBM, CNKI, et al. Used RevMan 5.2 to analyze. Results There were 19 clinical trials that met the inclusion criteria, Meta-analysis revealed that, Aiyishu injection combined chemotherapy produced a moderately improvement for a higher effective rate [RR=1.42, 95%CI （1.25, 1.61）], and patients’ quality of life [RR=1.63, 95%CI （1.26, 2.11）], while effectively reduced clinical symptoms [RR=1.54, 95%CI （1.28, 1.86）], bone marrow suppression （mainly leukocytes） [RR=0.47, 95% CI （0.35, 0.63）] and incidence of gastrointestinal symptoms [RR=0.73, 95% CI （0.61, 0.88）]. Conclusion Aiyishu injection combined chemotherapy may be beneficial to the attenuated synergy of lung carcinoma therapy

关 键 词：肺肿瘤 随机对照试验 艾易舒注射液 系统评价 

分 类 号：R734.2[医药卫生—肿瘤]